According to Bloomberg, 3.19 million shares were traded in multiple block deals. Buyers and sellers of the transactions were ...

Biocon eyes global insulin leadership as rivals pivot to GLP-1 therapies, betting on capacity gaps, pricing advantage and ...

In the last one year, shares of Biocon zoomed up to 17 per cent, while on a year-to-date basis it cracked over 13 per cent.

BENGALURU, India & BRIDGEWATER, N.J.-- (BUSINESS WIRE)--Apr 7, 2026-- ...

Viatris is leaving the biosimilar field just months after winning the landmark FDA approval for the first interchangeable biosimilar product. Biocon Biologics, a subsidiary of Biocon, will buy Viatris ...

The biosimilar fracas targeting AbbVie’s megablockbuster Humira is taking shape. But to Biocon Biologics CEO Shreehas Tambe, the battle doesn’t solely revolve around market share. Humira, also known ...

Profit rises 71% YoY to Rs 144 crore Biocon Biologics share which constitutes 45% of revenues reported 29% YoY growth to Rs ...

Appointment expands HR leadership across regions as Biocon scales global operations and talent strategy. Biocon has appointed ...

Biocon aims to become the world's leading insulin company, capitalising on larger pharmaceutical rivals' strategic shift ...

Biocon, a biopharma giant, is escalating its artificial intelligence adoption across all operations to expedite drug ...

Viatris Inc. , the company formed by the merger of Mylan and Pfizer Inc. unit Upjohn in 2020, said Monday it has reached an agreement to combine its biosimilars portfolio with Biocon Biologics Ltd.

Biocon’s fair value estimate has been adjusted slightly, moving from ₹421.60 to ₹420.74, a change of less than 1% that keeps the price target broadly in line with earlier expectations. Analysts ...